NASDAQ:NVIV InVivo Therapeutics (NVIV) Stock Price, News & Analysis → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free NVIV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.22▼$0.7952-Week Range N/AVolume1.89 million shsAverage Volume8.25 million shsMarket Capitalization$997,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesShort InterestSocial MediaStock AnalysisEarningsHeadlinesShort InterestSocial Media Get InVivo Therapeutics alerts: Email Address Ad True Market Insiders4 Cryptos BETTER than BitcoinFormer Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About InVivo Therapeutics Stock (NASDAQ:NVIV)InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.Read More Ad True Market Insiders4 Cryptos BETTER than BitcoinFormer Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 NVIV Stock News HeadlinesMay 17, 2024 | investing.comInVivo Therapeutics Holdings Corp (NVIVQ)March 28, 2024 | msn.comGut health supplements are everywhere – but which are the best ones for *you*?February 15, 2024 | cnn.comInVivo Therapeutics Holdings CorporationFebruary 14, 2024 | wsj.comInVivo Therapeutics Holdings Corp.February 13, 2024 | wsj.comFirm Retention Summary: InVivo Therapeutics HoldingsFebruary 7, 2024 | investing.comInVivo Therapeutics Holdings Corp (NVIV)February 6, 2024 | bizjournals.comBob Langer-founded device-maker declares bankruptcyFebruary 6, 2024 | investorplace.comWhy Is InVivo Therapeutics (NVIV) Stock Up 61% Today?February 1, 2024 | marketwatch.comInVivo Therapeutics Shares Plumb New Depths After Bankruptcy FilingNovember 10, 2023 | morningstar.comInVivo Therapeutics Holdings Corp NVIVJune 22, 2023 | marketwatch.comSpinal Cord Trauma Treatment Market Analysis: Examining Trends and Forecasting Revenue Growth with an estimated CAGR 6.2% from 2023-2030May 1, 2023 | benzinga.comRing Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate StrategyMarch 17, 2023 | finance.yahoo.comWhy InVivo Therapeutics Shares Are Plunging TodayMarch 10, 2023 | msn.comInVivo seeks longer-term control in Casino-Teract retail tie-upMarch 10, 2023 | msn.comWhy Barnes & Noble Education Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving PremarketMarch 10, 2023 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.66%March 9, 2023 | msn.comWhy JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionMarch 9, 2023 | markets.businessinsider.comInVivo : INSPIRE 2.0 Study In Acute Spinal Cord Injury Fails To Meet Primary EndpointMarch 9, 2023 | msn.comInVivo to evaluate strategic options as trial for spinal injury device failsMarch 9, 2023 | marketwatch.comInVivo Therapeutics Shares Hit 52-Week Low After Study Misses Primary EndpointMarch 9, 2023 | marketwatch.comInVivo Therapeutics Study for Neuro-Spinal Scaffold Misses Primary EndpointMarch 9, 2023 | finance.yahoo.comInVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord InjuryJanuary 11, 2023 | benzinga.comInVivo Therapeutics Hldg Stock (NASDAQ:NVIV), Quotes and News SummaryOctober 11, 2022 | finance.yahoo.comInVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq RulesOctober 10, 2022 | marketwatch.comInVivo Therapeutics Shares Continue Friday's Fall, Hit All-Time Intraday LowSee More Headlines Receive NVIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2020Today5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVIV CUSIPN/A CIK1292519 Webwww.invivotherapeutics.com Phone(617) 863-5500FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-75.04% Return on Assets-65.01% Debt Debt-to-Equity RatioN/A Current Ratio14.30 Quick Ratio14.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.48 per share Price / BookN/AMiscellaneous Outstanding Shares3,110,000Free Float3,029,000Market Cap$997,000.00 OptionableNot Optionable Beta0.65 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Richard M. Toselli M.D. (Age 66)President, CEO, Chief Medical Officer & Director Comp: $825.2kMr. Richard C. Christopher (Age 54)CFO & Treasurer Comp: $537.82kMs. Heather M. Hamel J.D. (Age 34)Chief Legal Officer & General Counsel Comp: $446.96kDr. Robert S. Langer Jr. (Age 75)Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Joseph Philip Vacanti M.D. (Age 75)Co-Founder Key CompetitorsAcutus MedicalNASDAQ:AFIBSintx TechnologiesNASDAQ:SINTProSomnusNASDAQ:OSAPNemaura MedicalNASDAQ:NMRDBluejay DiagnosticsNASDAQ:BJDXView All Competitors NVIV Stock Analysis - Frequently Asked Questions How were InVivo Therapeutics' earnings last quarter? InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) announced its quarterly earnings data on Wednesday, May, 13th. The biotechnology company reported ($61.75) earnings per share for the quarter. When did InVivo Therapeutics' stock split? InVivo Therapeutics's stock reverse split before market open on Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of InVivo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares Preferred and Income Securities ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), Apollo Investment (AINV), IVERIC bio (OPHT), OPKO Health (OPK) and Cardiff Oncology (TROV). This page (NASDAQ:NVIV) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InVivo Therapeutics Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.